Evidence map›Paper›PMID 40571866›Full record

ArticleThe AAPS journal2025

Enhanced Nanoprecipitation Method for the Production of PLGA Nanoparticles for Oncology Applications.

Hany Sadek Ayoub Ghaly, Naisana Seyedasli, Pegah Varamini

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles.Journal of functional biomaterials · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hany Sadek Ayoub GhalySchool of Pharmacy (A15), University of Sydney, Sydney, NSW, 2006, Australia.
Naisana SeyedasliSchool of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, NSW, 2145, Australia.
Pegah VaraminiSchool of Pharmacy (A15), University of Sydney, Sydney, NSW, 2006, Australia. pegah.varamini@sydney.edu.au.ORCID 0000-0001-8658-9722

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we report a new modified nanoprecipitation method for the fabrication of water-dispersible Poly(lactic-co-glycolic acid) (PLGA) nanoparticles encapsulating three poorly water-soluble anticancer agents as model drugs: paclitaxel (PTX), docetaxel (DTX) or curcumin (Cur). These nanoparticles were water dispersible with favourable size for anticancer applications (below 200 nm) and relatively high drug loading (6.3-8.9%). These nanoparticles were stable for four weeks in solid state and up to 48 h when dispersed in water. PTX and Cur nanoparticles showed a very minimal release of the payload during a 72-h in vitro release study. The new method also yielded reproducible results across three different batches of each type of nanoparticles and following three times upscaling of PTX nanoparticles. PTX and Cur nanoparticles were more effective than the free drugs against MDA-MB-231 cells (p < 0.05). In addition, PTX nanoparticles showed a significant enhanced induction of early apoptosis in MDA-MB-231 cells (42.3%) in comparison to free PTX (23.7%, p < 0.05). Both flow cytometry and confocal microscopy confirmed the uptake of the nanoparticles by MDA-MB-231 cells. In conclusion, our modified nanoprecipitation method produces PLGA nanoparticles loaded with different anticancer agents and suitable for cancer therapy.

Indexed as

Antineoplastic AgentsDrug CarriersLactic AcidNanoparticlesPolyglycolic AcidApoptosisCell Line, TumorChemical PrecipitationCurcuminDocetaxelHumansPaclitaxelParticle SizePolylactic Acid-Polyglycolic Acid CopolymerAntineoplastic AgentsCurcuminDocetaxelDrug CarriersLactic AcidPaclitaxelPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerCurcuminDocetaxelNanoparticlesPaclitaxelPLGA

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.